NCT00149981

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties

Detailed description

This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression. The objectives are to facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials, * To provide everolimus maintenance therapy through this access program and * To collect and review safety data for up to 120 months or until the project has been discontinued whichever comes first. * To collect and review safety data for up to 120 months or when Certican is commercially available in the given indication and reimbursed by appropriate payors or the project has been discontinued whichever comes first.

Conditions

• Organ Transplantation

Interventions

Type	Name	Description
DRUG	everolimus (RAD)	Everolimus

Timeline

• First posted: 2005-09-08
• Last updated: 2019-09-09

Locations

153 sites across 19 countries: United States, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, New Zealand, Norway, Poland, Puerto Rico, Russia, South Africa, Spain, Switzerland, Taiwan, United Kingdom